Autolus Therapeutics Q3 2026 Earnings Date & Estimates

Autolus Therapeutics (NASDAQ:AUTL) plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for the treatment of cancer. The company’s platform is designed to genetically engineer T cells so they can recognize cancer targets, remain active in the body, and potentially reduce some limitations associated with conventional cell therapies.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States as Aucatzyl. In November 2024, the U.S. Food and Drug Administration approved Aucatzyl for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus has also developed additional investigational T-cell programs targeting hematologic malignancies and solid tumors.

Founded in 2014 and headquartered in London, Autolus operates across the United Kingdom and the United States, where it conducts research, clinical development, regulatory, and commercial activities. The company’s operations include manufacturing and delivering personalized cell therapies, as well as advancing its broader pipeline of engineered T-cell treatments.